AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de la Campa, A. G.
Right arrow Articles by Liñares, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de la Campa, A. G.
Right arrow Articles by Liñares, J.
Antimicrobial Agents and Chemotherapy, April 2003, p. 1419-1422, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1419-1422.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Genetic Characterization of Fluoroquinolone-Resistant Streptococcus pneumoniae Strains Isolated during Ciprofloxacin Therapy from a Patient with Bronchiectasis

Adela G. de la Campa,1* María-José Ferrandiz,1,{dagger} Fe Tubau,2 Román Pallarés,3 Federico Manresa,4 and Josefina Liñares2

Unidad de Genética Bacteriana (Consejo Superior de Investigaciones Científicas), Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid,1 Servicio de Microbiología,2 Servicio de Enfermedades Infecciosas,3 Servicio de Neumología, Hospital de Bellvitge and Universidad de Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain4

Received 20 September 2002/ Returned for modification 13 November 2002/ Accepted 15 January 2003

Five Spain9V-3 Streptococcus pneumoniae strains were isolated from a patient with bronchiectasis who had received long-term ciprofloxacin therapy. One ciprofloxacin-susceptible strain was isolated before treatment, and four ciprofloxacin-resistant strains were isolated during treatment. The resistant strains were derived from the susceptible strain either by a parC mutation (low-level resistance) or by parC and gyrA mutations (high-level resistance). This study shows that ciprofloxacin therapy in a patient colonized by susceptible S. pneumoniae may select fluoroquinolone-resistant mutants.


* Corresponding author. Mailing address: Unidad de Genética Bacteriana (Consejo Superior de Investigaciones Científicas), Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain. Phone: (341) 509-7904. Fax: (341) 509-7919. E-mail: agcampa{at}isciii.es.

{dagger} Present address: Institute of Infection and Immunity, Nottingham, United Kingdom.


Antimicrobial Agents and Chemotherapy, April 2003, p. 1419-1422, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1419-1422.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2003 by the American Society for Microbiology. All rights reserved.